2024
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2
Bell J, Davies E, Brereton C, Vukmirovic M, Roberts J, Lunn K, Wickens L, Conforti F, Ridley R, Ceccato J, Sayer L, Johnston D, Vallejo A, Alzetani A, Jogai S, Marshall B, Fabre A, Richeldi L, Monk P, Skipp P, Kaminski N, Offer E, Wang Y, Davies D, Jones M. Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2. Cell Reports Medicine 2024, 5: 101695. PMID: 39173635, PMCID: PMC11524965, DOI: 10.1016/j.xcrm.2024.101695.Peer-Reviewed Original Research
2016
Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension
Fares WH, Bellumkonda L, Tonelli AR, Carson SS, Hassoun PM, Trow TK, Herzog EL, Kaminski N, Kholdani CA, Zhang L, Zhou Y, Hammel JP, Dweik RA. Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension. The Journal Of Heart And Lung Transplantation 2016, 35: 760-767. PMID: 26856665, DOI: 10.1016/j.healun.2015.12.028.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionHemodynamic variablesArterial hypertensionCohort 2Cohort 1Accurate prognostic variableRelative prognostic valueSpecific predictorsCurrent prognostic modelsMultivariable regression modelsPAH registryPAH patientsHazard ratioPAH cohortReferral centerPrognostic valueMean ageClinical trialsClinical prognosticationPrognostic variablesSeparate cohortDisease statusFatal diseasePrognostic modelSecondary analysis
2013
Activation of Human Mesenchymal Stem Cells Impacts Their Therapeutic Abilities in Lung Injury by Increasing Interleukin (IL)-10 and IL-1RN Levels
Bustos ML, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sciurba JD, Mroz L, McVerry BJ, Ellis BM, Kaminski N, Rojas M. Activation of Human Mesenchymal Stem Cells Impacts Their Therapeutic Abilities in Lung Injury by Increasing Interleukin (IL)-10 and IL-1RN Levels. Stem Cells Translational Medicine 2013, 2: 884-895. PMID: 24089414, PMCID: PMC3808203, DOI: 10.5966/sctm.2013-0033.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeAnti-inflammatory effectsBone marrow aspirateReceptor antagonistMarrow aspiratesMesenchymal stem cellsBronchoalveolar lavage inflammatory cellsIL-1 receptor antagonistHuman mesenchymal stem cellsLung injury scoreRespiratory distress syndromeAnti-inflammatory capacityExpression of interleukinStem cellsARDS patientsLung inflammationLung injuryDistress syndromeEndotoxemic micePulmonary edemaInflammatory cellsInjury scoreClinical trialsEffective therapyImmunomodulatory phenotypeAssociation Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA. Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis. JAMA 2013, 309: 2232-2239. PMID: 23695349, PMCID: PMC4545271, DOI: 10.1001/jama.2013.5827.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisChicago cohortPulmonary fibrosisImproved survivalPromoter polymorphismInterstitial lung disease clinicMUC5B Promoter PolymorphismPrimary end pointNumber of patientsTT genotype groupCommon risk polymorphismsChicago patientsIPF mortalityMedian followCause mortalityCumulative incidenceMechanisms of diseaseDisease clinicRetrospective studyVital capacityClinical trialsBlood concentrationsClinical covariatesMAIN OUTCOMETreatment status
2010
Inhibition and Role of let-7d in Idiopathic Pulmonary Fibrosis
Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, Konishi K, Yousem SA, Singh M, Handley D, Richards T, Selman M, Watkins SC, Pardo A, Ben-Yehudah A, Bouros D, Eickelberg O, Ray P, Benos PV, Kaminski N. Inhibition and Role of let-7d in Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 220-229. PMID: 20395557, PMCID: PMC2913236, DOI: 10.1164/rccm.200911-1698oc.Peer-Reviewed Original ResearchMeSH KeywordsActinsAnimalsCadherinsCells, CulturedDown-RegulationEpithelial CellsHMGA2 ProteinHumansIdiopathic Pulmonary FibrosisIn Situ HybridizationLungMiceMice, Inbred C57BLMicroRNAsPolymerase Chain ReactionPulmonary AlveoliS100 Calcium-Binding Protein A4S100 ProteinsSmad3 ProteinTransforming Growth Factor betaVimentinConceptsIdiopathic pulmonary fibrosisReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionAlveolar epithelial cellsIPF lungsPulmonary fibrosisPolymerase chain reactionLet-7dEpithelial cellsLethal fibrotic lung diseaseAlpha-smooth muscle actinAlveolar septal thickeningMesenchymal markers N-cadherinFibrotic lung diseaseChain reactionLet-7d expressionSeptal thickeningPulmonary functionLung diseaseLung fibrosisEpithelial cell lineIntratracheal administrationIPF tissueProfibrotic effectsClinical trials